Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
Document Type
Journal Article
Publication Date
7-1-2020
Journal
Lancet HIV
Volume
7
Issue
7
Inclusive Pages
e472-e481
DOI
10.1016/S2352-3018(20)30106-5
APA Citation
Landovitz, R., Li, S., Eron, J., Grinsztejn, B., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M., Eshleman, S., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A., Margolis, D., Cohen, M., McCauley, M., & Hendrix, C. (2020). Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.. Lancet HIV, 7 (7). http://dx.doi.org/10.1016/S2352-3018(20)30106-5
Peer Reviewed
1
Comments
Epub 2020 Jun 1